Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 | P18405 | 9/20 | 0.53 |
| ▸ | SRD5A2 | P31213 | 9/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.53 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.53 |
| ▸ | HSD3B1 | P14060 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | THPO | P40225 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL950330 | 1.00 | SRD5A1 (0.53) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL790657 | 1.00 | SRD5A1 (0.53) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| Imidazole SCHEMBL9187249 | 0.88 | SRD5A2 (0.45) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL6673554 | 0.85 | SRD5A1 (0.42) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL8059923 | 0.81 | SRD5A1 (0.48) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL8135268 | 0.81 | SRD5A1 (0.53) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL8135264 | 0.81 | SRD5A1 (0.53) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL4263946 | 0.80 | SRD5A1 (0.53) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL4263941 | 0.80 | SRD5A1 (0.53) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL7901226 | 0.79 | SRD5A1 (0.55) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7872135-B2 | Method for introducing a 1,2-double bond into 3-oxo-4-azasteroid compounds | SIEGFRIED LTD. (CH) | 2011-01-18 | — | — | US | claimed |
| EP-1523490-B1 | METHOD FOR INTRODUCING A 1,2 DOUBLE BOND INTO 3-OXO-4-AZASTEROID COMPOUNDS | SIEGFRIED GENERICS INT AG (CH) | 2009-12-23 | — | — | EP | claimed |
| US-20060100434-A1 | Method for introducing a 1,2-double bond into 3-oxo-4-azasteroid compounds | SIEGFRIED LTD. (CH) | 2006-05-11 | — | — | US | claimed |
| EP-1335930-B1 | Process for the preparation of 3-oxo-4-azasteroids | GLAXO GROUP LTD (GB) | 2004-10-13 | — | — | EP | claimed |
| US-6794508-B2 | Process | SMITHKLINE BEECHAM CORPORATION | 2004-09-21 | — | — | US | claimed |
| US-20040049042-A1 | Process | SMITHKLINE BEECHAM CORPORATION | 2004-03-11 | — | — | US | claimed |
| EP-1335930-A2 | PROCESS | GLAXO GROUP LIMITED (GB) | 2003-08-20 | — | — | EP | claimed |
| WO-2002046207-A2 | PROCESS | GLAXO GROUP LIMITED (GB) | 2002-06-13 | — | — | WO | claimed |
| EP-0862556-A4 | 17-ALKYL-7-SUBSTITUTED-4-AZA STEROID DERIVATIVES | MERCK & CO INC (US) | 1999-02-03 | — | — | EP | claimed |
| EP-0862556-A1 | 17-ALKYL-7-SUBSTITUTED-4-AZA STEROID DERIVATIVES | Merck & Co., Inc. (US) | 1998-09-09 | — | — | EP | claimed |
| WO-1998009632-A1 | METHODS AND COMPOSITIONS FOR TREATING PRETERM LABOR | MERCK & CO., INC. (US) | 1998-03-12 | — | — | WO | claimed |
| WO-1997015558-A1 | 17-ALKYL-7-SUBSTITUTED-4-AZA STEROID DERIVATIVES | MERCK & CO., INC. (US) | 1997-05-01 | — | — | WO | claimed |
| EP-0649431-A4 | 17-AMINO SUBSTITUTED 4-AZASTEROID 5-G(A)-REDUCTASE INHIBITORS. | — | 1995-05-03 | — | — | EP | claimed |
| EP-0649431-A1 | 17-AMINO SUBSTITUTED 4-AZASTEROID 5$g(a)-REDUCTASE INHIBITORS | MERCK & CO. INC. (US) | 1995-04-26 | — | — | EP | claimed |
| US-8591874-B2 | Inhibition of mammalian hair growth | THE PROCTER & GAMBLE COMPANY (US) | 2013-11-26 | — | — | US | disclosed |
| US-8481015-B2 | Applying agmatine and a dermatologically acceptable carrier to the skin; inhibiting hair growth | THE PROCTER & GAMBLE COMPANY (US) | 2013-07-09 | — | — | US | disclosed |
| US-7872135-B2 | Method for introducing a 1,2-double bond into 3-oxo-4-azasteroid compounds | SIEGFRIED LTD. (CH) | 2011-01-18 | — | — | US | disclosed |
| US-4760071-A | Enzyme inhibitor | MERCK & CO., INC. (US) | 1988-07-26 | — | — | US | disclosed |
| EP-0271219-A1 | Topical pharmaceutical composition containing 17-beta-methoxycarbonyl-4-methyl-4-aza-5-alpha-androst-1-en-3-one | MERCK & CO. INC. (US) | 1988-06-15 | — | — | EP | disclosed |
| EP-0155096-A2 | 17 Beta-Substituted-4-aza-5-alpha-androstenones and their use as 5-alpha-reductase inhibitors | MERCK & CO. INC. (US) | 1985-09-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100434-A1 | Method for introducing a 1,2-double bond into 3-oxo-4-azasteroid compounds | NR3C2, NR5A1, CYP11B1 | SRD5A1 14/4885SRD5A2 7/4885LMNA 1712/4885 |
| US-20040049042-A1 | Process | SRD5A2, SRD5A1, HSD3B1 | SRD5A1 2/4885SRD5A2 1/4885LMNA 4692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.